1. Home
  2. MEIP vs GLXG Comparison

MEIP vs GLXG Comparison

Compare MEIP & GLXG Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • MEIP
  • GLXG
  • Stock Information
  • Founded
  • MEIP 2000
  • GLXG 2013
  • Country
  • MEIP United States
  • GLXG Hong Kong
  • Employees
  • MEIP N/A
  • GLXG N/A
  • Industry
  • MEIP Biotechnology: Pharmaceutical Preparations
  • GLXG
  • Sector
  • MEIP Health Care
  • GLXG
  • Exchange
  • MEIP Nasdaq
  • GLXG NYSE
  • Market Cap
  • MEIP 16.3M
  • GLXG 15.8M
  • IPO Year
  • MEIP 2003
  • GLXG 2024
  • Fundamental
  • Price
  • MEIP $2.87
  • GLXG $1.22
  • Analyst Decision
  • MEIP Hold
  • GLXG
  • Analyst Count
  • MEIP 2
  • GLXG 0
  • Target Price
  • MEIP $7.00
  • GLXG N/A
  • AVG Volume (30 Days)
  • MEIP 36.2K
  • GLXG 3.2M
  • Earning Date
  • MEIP 02-11-2025
  • GLXG 02-16-2025
  • Dividend Yield
  • MEIP N/A
  • GLXG N/A
  • EPS Growth
  • MEIP N/A
  • GLXG N/A
  • EPS
  • MEIP N/A
  • GLXG 0.04
  • Revenue
  • MEIP N/A
  • GLXG $3,858,088.00
  • Revenue This Year
  • MEIP N/A
  • GLXG N/A
  • Revenue Next Year
  • MEIP $300.00
  • GLXG N/A
  • P/E Ratio
  • MEIP N/A
  • GLXG $27.68
  • Revenue Growth
  • MEIP 33.76
  • GLXG N/A
  • 52 Week Low
  • MEIP $2.30
  • GLXG $0.70
  • 52 Week High
  • MEIP $4.97
  • GLXG $16.93
  • Technical
  • Relative Strength Index (RSI)
  • MEIP 66.22
  • GLXG N/A
  • Support Level
  • MEIP $2.56
  • GLXG N/A
  • Resistance Level
  • MEIP $2.78
  • GLXG N/A
  • Average True Range (ATR)
  • MEIP 0.15
  • GLXG 0.00
  • MACD
  • MEIP 0.04
  • GLXG 0.00
  • Stochastic Oscillator
  • MEIP 100.00
  • GLXG 0.00

About MEIP MEI Pharma Inc.

MEI Pharma Inc is focused on the clinical development of novel therapies for cancer. The company's clinical drug candidate includes Pracinostat, an orally available histone deacetylase inhibitor for the treatment of patients with acute myeloid leukemia and myelodysplastic syndrome. Its clinical development portfolio also includes Zandelisib, an oral inhibitor of phosphatidylinositide 3-kinase delta for the treatment of patients with recurrent chronic lymphocytic leukemia or follicular non-Hodgkin's lymphoma; and ME-344, an isoflavone-based mitochondrial inhibitor for the treatment of HER2-negative breast cancer and Pracinostat, an oral histone deacetylase inhibitor. Geographically, all the business activities function through the region of the United States.

About GLXG GALAXY PAYROLL GROUP LTD

Galaxy Payroll Group Ltd provides payroll outsourcing, employment, consultancy, and market research services based in Hong Kong. Its client base includes retail, trading, industrial, IT, financial, and professional services industries. Geographically, the company derives maximum revenue from its clients in the People's Republic of China and the rest from Hong Kong, Macau, Taiwan, Japan, Thailand, Singapore, and other countries.

Share on Social Networks: